Specifically, among the 51,783 lung cancer patients with detectable ctDNA, 2,398 patients (4.63%) had tumors with non-overlapping BRAF mutations belonging to one of the three functional classes (Class I, II, or III only) (Supplementary Fig. 1b). This evidence concerns the gene BRAF and lung cancer.